Literature DB >> 26581710

TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.

Koji Mukasa1, Jaeduk Yoshimura Noh, Ai Kouzaki, Hidemi Ohye, Yo Kunii, Natsuko Watanabe, Ai Yoshihara, Masako Matsumoto, Miho Suzuki, Koichi Ito.   

Abstract

TSH receptor antibody (TRAb) titer has been reported to be correlated with Graves' ophthalmopathy (GO). However, the correlation between GO activity and TRAb titer assessed with a third-generation assay has not been reported. We enrolled 238 untreated Graves' disease patients who came to the outpatient clinic of Ito Hospital and 28 patients who were euthyroid. All of the patients were assessed for GO by an ophthalmologist within 3 months of their initial visit to Ito Hospital. Clinical activity score (CAS), short inversion time inversion recovery (STIR), and sum of the maximum external orbital muscle areas (SEOMA) on a frontal sectional magnetic resonance imaging (MRI). The TRAb titer was significantly higher in patients with inactive ophthalmopathy (the inactive-GO group) than in patients with active ophthalmopathy (the active-GO group) (17.7 ± 13.5 IU/L vs. 13.0 ± 13.1 IU/L, p=0.0082). The SEOMA values were not correlated with TRAb titer. The prevalence of active-GO was higher in euthyroid patients than in hyperthyroid patients although the difference was not significant. In conclusion, TRAb titer measured with a third-generation assay dose not correlate with GO activity based on MRI findings in untreated Graves' disease patients, and the prevalence of active-GO is higher in euthyroid patients with lower TRAb titers than in hyperthyroid patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581710     DOI: 10.1507/endocrj.EJ15-0137

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

1.  Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Authors:  S Seo; M Sánchez Robledo
Journal:  J Endocrinol Invest       Date:  2018-09-07       Impact factor: 4.256

2.  TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.

Authors:  Christine C Krieger; Robert F Place; Carmine Bevilacqua; Bernice Marcus-Samuels; Brent S Abel; Monica C Skarulis; George J Kahaly; Susanne Neumann; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2016-04-04       Impact factor: 5.958

3.  Clinical efficacy of transcutaneous triamcinolone acetonide injection for upper eyelid retraction and swelling in patients with thyroid eye disease.

Authors:  Ai Kozaki; Hiroshi Nakamura; Toshu Inoue
Journal:  Int Med Case Rep J       Date:  2018-11-09

4.  Risk Factors Associated with the Activity and Severity of Graves' Ophthalmopathy among Patients at the University of the Philippines Manila-Philippine General Hospital.

Authors:  Annabelle Marie Lat; Maria Cristina Jauculan; Charisse Ann Sanchez; Cecilia Jimeno; Cherrie Mae Sison-Peña; Mary Rose Pe-Yan; Paulo Ma Pagkatipunan; Armida Suller; Marianne Cena
Journal:  J ASEAN Fed Endocr Soc       Date:  2017-09-07

5.  Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Maria Camila Sierra-Cote; Estefanía Zapata-Bravo; Laura Valenzuela-Vallejo; Maria Alejandra Marin-Noriega; Pilar Uribe-Reina; Juan Pablo Terreros-Dorado; Marcela Gómez-Suarez; Karla Arteaga-Rivera; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2020-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.